APGE
Apogee Therapeutics Inc
NASDAQ · Biotechnology
$62.24
+0.11 (+0.18%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 911.35M | 871.62M | 948.06M |
| Net Income | -243,438,723 | -174,175,180 | -203,637,440 |
| EPS | — | — | — |
| Profit Margin | -26.7% | -20.0% | -21.5% |
| Rev Growth | +22.2% | +5.3% | +12.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.26B | 1.19B | 976.56M |
| Total Equity | 1.43B | 1.41B | 1.64B |
| D/E Ratio | 0.88 | 0.85 | 0.60 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -267,934,128 | -228,786,100 | -261,593,713 |
| Free Cash Flow | -101,879,133 | -97,401,406 | -128,866,616 |